Wang Huiyu, Gu Dingyi, Chen Datian, Mei Jie, Yang Xuejing, Ding Junli, Xu Junying, Wang Meilin, Liu Chaoying, Hua Dong
Comprehensive Cancer Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, People's Republic of China.
Department of Oncology, Haimen People's Hospital Affiliated to Nantong University, Haimen, 226100, People's Republic of China.
Int J Gen Med. 2022 Sep 19;15:7383-7393. doi: 10.2147/IJGM.S381530. eCollection 2022.
The aim of this study was to explore the clinical significance of deglycosylated PD-L1 level and its correlation with EGFR and ALK mutation in lung adenocarcinoma.
We estimated the intensity of both native and deglycosylated PD-L1 signals using a 28-8 antibody on lung adenocarcinoma tissue microarray sections. We analyzed the difference in the H-score between tumor and paratumor tissues, as well as that before and after deglycosylation. Correlations between EGFR or ALK status and PD-L1 expression were analyzed. We also evaluated the differences among survival curves.
The expression level of PD-L1 in lung adenocarcinoma tissues was significantly higher than that in paratumor tissues (P<0.0001). Deglycosylation significantly enhanced the detection of PD-L1 in tumor tissues (P<0.0001). There was no statistical significance between the signal intensity of deglycosylated PD-L1 and the survival of patients (P=0.9099). However, the response to deglycosylation of PD-L1 was significantly correlated with the survival of patients with stage N1-N3 (P=0.0435) and stage T3-T4 (P=0.0366) and male patients (P=0.0258). A statistical trend was found in the correlation between the response to deglycosylation of PD-L1 and the survival of patients with grade II-III plus grade III (P=0.0973). Correlation between EGFR or ALK status and the expression of PD-L1 was not found (P>0.05).
PD-L1 deglycosylation enhances the detection of PD-L1 when utilizing a 28-8 antibody. Moreover, the response to deglycosylation of PD-L1 may predict the survival of certain patients with lung adenocarcinoma.
本研究旨在探讨去糖基化PD-L1水平在肺腺癌中的临床意义及其与表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）突变的相关性。
我们使用28-8抗体在肺腺癌组织微阵列切片上评估天然和去糖基化PD-L1信号的强度。我们分析了肿瘤组织和癌旁组织之间以及去糖基化前后H评分的差异。分析了EGFR或ALK状态与PD-L1表达之间的相关性。我们还评估了生存曲线之间的差异。
肺腺癌组织中PD-L1的表达水平显著高于癌旁组织（P<0.0001）。去糖基化显著增强了肿瘤组织中PD-L1的检测（P<0.0001）。去糖基化PD-L1的信号强度与患者生存率之间无统计学意义（P=0.9099）。然而，PD-L1去糖基化反应与N1-N3期（P=0.0435）、T3-T4期（P=0.0366）患者及男性患者（P=0.0258）的生存率显著相关。在PD-L1去糖基化反应与II-III级加III级患者生存率之间的相关性中发现了统计学趋势（P=0.0973）。未发现EGFR或ALK状态与PD-L1表达之间的相关性（P>0.05）。
当使用28-8抗体时，PD-L1去糖基化增强了PD-L1的检测。此外，PD-L1去糖基化反应可能预测某些肺腺癌患者的生存率。
